

# Aptar Active Material Science Advances N-Sorb Technology

Thermo Fisher introduces M Series Centrifuges.



**Aptar Active Material Science, part of** AptarGroup, Inc. and a global provider of active material science solutions, has announced a significant intellectual property milestone in its nitrosamine risk mitigation platform. The company's foundational U.S. patent application for its N-Sorb technology has been approved by the U.S. Patent and Trademark Office (USPTO).

The N Sorb technology uniquely integrates material science innovation with demonstrated performance on drug products, establishing a new standard for packaging-delivered mitigation of nitrosamine impurities.

N Sorb technology can be deployed across multiple packaging configurations, including blister systems, bottle formats (including drop-in solutions), and film-based structures, enabling integration without changes to formulation or manufacturing processes.

The patent application encompasses both the proprietary material composition and validated reduction of nitrosamines across multiple active pharmaceutical ingredients (APIs) known to exhibit nitrosamine vulnerability. This extends the N Sorb technology platform beyond traditional packaging IP into performance-

driven protection.

The patent application includes provisions that can support potential listing in the FDA Orange Book, a public registry of all FDA-approved drugs based on safety and effectiveness. The patent application demonstrates the technology's performance on drug products and explicitly names many APIs with nitrosamine susceptibility. As such, pharmaceutical partners utilizing N Sorb technology may have the opportunity to pursue enhanced regulatory and commercial protection strategies tied to finished product performance.

"This milestone marks a fundamental shift in how the industry can address nitrosamine risk," said Badre Hammond, VP, Global Commercial Operations and GM, APAC for Aptar Active Material Science. "For the first time, we are bringing together advanced material science and demonstrated drug product performance within a single IP framework. That combination creates a powerful new lever for our pharmaceutical partners to mitigate risk and establish differentiated regulatory and commercial positions (i.e. Orange Book listing). This is a platform innovation with broad implications for product integrity, lifecycle management, and patient safety."

In August 2024, N-SorbSM technology was accepted to the U.S. FDA's Emerging Technology Program (ETP), which aims to identify and resolve potential technical and regulatory issues related to novel technologies prior to regulatory submission. The program promotes the adoption of innovative approaches to product design and manufacturing, facilitating industry modernization and reducing timeframes and costs for introducing novel solutions.

**More info:** [www.aptar.com](http://www.aptar.com)

## THERMO FISHER INTRODUCES M SERIES CENTRIFUGES

**Thermo Fisher Scientific has introduced** the Thermo Scientific M Series Centrifuges, designed to deliver precise performance in a compact footprint to support centrifugation across clinical, pharma research and academic research laboratories.

The M Series Centrifuges are designed to integrate seamlessly into laboratory workflows and support more sustainable lab workflows. They offer several rotor options, including dual-row and micro-volume processing, enabling researchers to run different sample types and volumes with a single centrifuge.

They also include Thermo Scientific GreenCool Technology featuring a

next-generation natural refrigerant (R600a). The M Series Centrifuges also offer 15% less energy consumption compared to previous models.

"The M Series Centrifuges help deliver the powerful performance needed by



modern labs combined with more sustainable innovation," said Noreen Hong, vice president and general manager of growth, protection and separation at